Guillain-Barré Syndrome Market: Rapid Increment Driven by Innovation by 2034 - DelveInsight

DelveInsight's "Guillain-Barré Syndrome Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Guillain-Barré Syndrome, historical and forecasted epidemiology as well as the Guillain-Barré Syndrome market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the Guillain-Barré Syndrome market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Guillain-Barré Syndrome Market Forecast
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the Guillain-Barré Syndrome Market Report:
• The Guillain-Barré Syndrome market size is anticipated to grow with a significant CAGR during the study period (2020-2034).
• In January 2026, Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company developing next-generation targeted immunotherapies for neuroinflammatory conditions affecting nearly 10 million people globally, announced that it has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for tanruprubart as a treatment for Guillain-Barré syndrome (GBS).
• In April 2025, A single dose of the investigational drug tanruprubart led to a rapid and sustained improvement in disability for patients with Guillain-Barré syndrome (GBS), according to results from a Phase III placebo-controlled study. The trial's primary endpoint-the GBS Disability Score (GBS-DS) at 8 weeks-revealed that 29% of patients receiving 30 mg/kg of tanruprubart achieved a score of 0 or 1, indicating a return to a healthy state, compared to just 12% in the placebo group (OR 2.41, P=0.0058).
• In January 2025, The FDA has mandated safety labeling updates for both RSV vaccines to include a warning about the rare neurological condition, Guillain-Barré Syndrome (GBS). This decision follows a postmarketing observational study assessing the risk of GBS after vaccination with Abrysvo and Arexvy. After evaluating clinical trial data, reports from the Vaccine Adverse Event Reporting System (VAERS), and findings from the postmarketing study, the FDA concluded that the collective evidence indicates a potential increased risk of GBS with these vaccines. However, the current data is not sufficient to confirm a definitive causal relationship.
• In December 2024, Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company focused on developing late-stage therapies for severe classical complement-mediated neuroinflammatory conditions affecting the body, brain, and eyes, has announced positive topline findings from a real-world evidence (RWE) study supporting the potential of ANX005 as a treatment for Guillain-Barré Syndrome (GBS). GBS is a rapidly progressing neuromuscular disorder that currently lacks any FDA-approved therapies. ANX005, the leading targeted immunotherapy in development for GBS, is designed to deliver a single-dose blockade of C1q and complement activity to stop disease progression during its critical early phase.
• As per the National Organization of Rare Disorders (NORD) (n.d.), Guillain-Barré Syndrome (GBS) impacts approximately one to two individuals annually per 100,000 population. The precise cause of this condition remains uncertain. It's noted that around half of those affected experience a gastrointestinal or respiratory infection in the days leading up to the onset of symptoms.
• The outlook for Guillain-Barré Syndrome (GBS) varies depending on its specific form. While some patients achieve full recovery, others may still face challenges with walking six months after the onset of the disease. In severe cases, GBS can unfortunately lead to a fatal outcome.
• Key Guillain-Barré Syndrome Companies: Japan Blood Products Organization, Nihon Pharmaceutical, Hansa Biopharma, Chafic Karam, Annexon, Inc., Alexion Pharmaceuticals, and others
• Key Guillain-Barré Syndrome Therapies: GB-0998, NPB-01, Imlifidase, Efgartigimod Alfa-Fcab, ANX005, Eculizumab, and others
• The Guillain-Barré Syndrome epidemiology based on gender analyzed that Guillain-Barré Syndrome is more common in men than in women
• The Guillain-Barré Syndrome market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Guillain-Barré Syndrome pipeline products will significantly revolutionize the Guillain-Barré Syndrome market dynamics.

Guillain-Barré Syndrome Overview
Guillain-Barré Syndrome (GBS) is a rare neurological disorder in which the body's immune system attacks the peripheral nerves. It often begins with weakness, tingling, or numbness in the extremities, which can progress to muscle weakness and, in severe cases, paralysis. The exact cause is unknown, but GBS is often triggered by infections, surgeries, or vaccinations. While most patients recover fully with proper treatment, including immunotherapy and supportive care, some may experience long-term nerve damage. Early diagnosis and intervention are crucial to managing symptoms and preventing complications.

Get a Free sample for the Guillain-Barré Syndrome Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Guillain-Barré Syndrome Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Guillain-Barré Syndrome Epidemiology Segmentation:
The Guillain-Barré Syndrome market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of Guillain-Barré Syndrome
• Prevalent Cases of Guillain-Barré Syndrome by severity
• Gender-specific Prevalence of Guillain-Barré Syndrome
• Diagnosed Cases of Episodic and Chronic Guillain-Barré Syndrome

Download the report to understand which factors are driving Guillain-Barré Syndrome epidemiology trends @ Guillain-Barré Syndrome Epidemiology Forecast
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Guillain-Barré Syndrome Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Guillain-Barré Syndrome market or expected to get launched during the study period. The analysis covers Guillain-Barré Syndrome market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Guillain-Barré Syndrome Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Guillain-Barré Syndrome Therapies and Key Companies
• GB-0998: Japan Blood Products Organization
• NPB-01: Nihon Pharmaceutical
• Imlifidase: Hansa Biopharma
• Efgartigimod Alfa-Fcab: Chafic Karam
• ANX005: Annexon, Inc.
• Eculizumab: Alexion Pharmaceuticals

Discover more about therapies set to grab major Guillain-Barré Syndrome market share @ Guillain-Barré Syndrome Treatment Landscape
https://www.delveinsight.com/sample-request/guillain-barre-syndrome-gbs-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Guillain-Barré Syndrome Market Drivers
• Rising incidence of autoimmune and post-infectious neurological disorders globally
• Increasing awareness and improved diagnosis of Guillain-Barré Syndrome (GBS) among clinicians
• Growing prevalence of triggering infections such as Campylobacter jejuni, influenza, and viral illnesses
• Advancements in supportive care, intensive care units, and neurological rehabilitation services
• Expanding use of established therapies like IV immunoglobulin (IVIG) and plasma exchange
• Ongoing research into novel immunomodulatory and targeted therapies
• Improved access to healthcare and neurological specialty centers in emerging markets

Guillain-Barré Syndrome Market Barriers
• Rarity of the disease, limiting patient pool and commercial attractiveness
• High treatment costs, particularly for IVIG and long hospital stays
• Limited availability of advanced therapies in low- and middle-income regions
• Absence of disease-specific targeted drugs beyond standard immunotherapies
• Diagnostic challenges due to symptom overlap with other neuromuscular disorders
• Stringent regulatory requirements and difficulties in conducting large clinical trials
• Long recovery periods and variable patient outcomes impacting treatment evaluation

Scope of the Guillain-Barré Syndrome Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Guillain-Barré Syndrome Companies: Japan Blood Products Organization, Nihon Pharmaceutical, Hansa Biopharma, Chafic Karam, Annexon, Inc., Alexion Pharmaceuticals, and others
• Key Guillain-Barré Syndrome Therapies: GB-0998, NPB-01, Imlifidase, Efgartigimod Alfa-Fcab, ANX005, Eculizumab, and others
• Guillain-Barré Syndrome Therapeutic Assessment: Guillain-Barré Syndrome current marketed and Guillain-Barré Syndrome emerging therapies
• Guillain-Barré Syndrome Market Dynamics: Guillain-Barré Syndrome market drivers and Guillain-Barré Syndrome market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• Guillain-Barré Syndrome Unmet Needs, KOL's views, Analyst's views, Guillain-Barré Syndrome Market Access and Reimbursement

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.